NEW YORK--(BUSINESS WIRE)--
Levi & Korsinsky announces it has commenced an investigation of Acorda Therapeutics, Inc. (“Acorda Therapeutics” or the “Company”) (NASDAQ: ACOR) concerning possible violations of federal securities laws.
On August 29, 2017, Acorda announced that it had received a Refusal to File letter from the U.S. Food and Drug Administration (the “FDA”), which informed the Company that its New Drug Application for INBRIJA (CVT-301) “was not sufficiently complete to permit a substantive review.” Among the reasons for the refusal, the FDA cited the date the manufacturing site would be ready for inspection and a question regarding the submission of the drug master production record. The FDA has requested further information at resubmission. Following this news, shares of Acorda were down more than 24% on intraday trading on August 28, 2017. To obtain additional information, go to:
http://www.zlkdocs.com/ACOR-Info-Request-Form-6067
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170829006094/en/
